ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1

Yunhao Chen,Yanchun Zhao,Junru Chen,Chuanhui Peng,Yanpeng Zhang,Rongliang Tong,Qiyang Cheng,Beng Yang,Xiaode Feng,Yuejie Lu,Haiyang Xie,Lin Zhou,Jian Wu,Shusen Zheng

DOI: https://doi.org/10.1186/s12943-020-01239-w

IF: 37.3

2020-08-10

Molecular Cancer

Abstract:Abstract Background N6-methyladenosine (m 6 A) modification is an emerging layer of epigenetic regulation which is widely implicated in the tumorigenicity of hepatocellular carcinoma (HCC), offering a novel perspective for investigating molecular pathogenesis of this disease. The role of AlkB homolog 5 (ALKBH5), one of the m 6 A demethylases, has not been fully explored in HCC. Here we clarify the biological profile and potential mechanisms of ALKBH5 in HCC. Methods Expression of ALKBH5 and its correlation with clinicopathological characteristics of HCC were evaluated using tissue microarrays and online datasets. And biological effects of ALKBH5 in HCC were determined in vitro and in vivo. Subsequently, methylated RNA immunoprecipitation sequencing (MeRIP-seq) combined with RNA sequencing (RNA-seq), and following m 6 A dot blot, MeRIP-qPCR, RIP-qPCR or dual luciferase reporter assays were employed to screen and validate the candidate targets of ALKBH5. Results We demonstrated that ALKBH5 was down-regulated in HCC, and decreased ALKBH5 expression was an independent prognostic factor of worse survival in HCC patients. Functionally, ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated m 6 A demethylation led to a post-transcriptional inhibition of LY6/PLAUR Domain Containing 1 (LYPD1), which could be recognized and stabilized by the m 6 A effector IGF2BP1. In addition, we identified that LYPD1 induced oncogenic behaviors of tumors in contrast to ALKBH5. Dysregulation of ALKBH5/LYPD1 axis impelled the progression of HCC. Conclusion Our study reveals that ALKBH5, characterized as a tumor suppressor, attenuates the expression of LYPD1 via an m 6 A-dependent manner in HCC cells. Our findings enrich the landscape of m 6 A-modulated tumor malignancy, and provide new insights into potential biomarkers and therapeutic targets of HCC treatment.

oncology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of AlkB homolog 5 (ALKBH5) in hepatocellular carcinoma (HCC) and its underlying mechanisms. Specifically, the researchers aim to:

1. **Evaluate the expression level of ALKBH5 in HCC**: Analyze the expression of ALKBH5 and its relationship with clinicopathological features through tissue microarrays and online databases.
2. **Determine the impact of ALKBH5 on the biological behavior of HCC cells**: Include in vitro and in vivo experiments to assess the influence of ALKBH5 on the proliferation and invasion ability of HCC cells.
3. **Reveal the mechanism of action of ALKBH5**: Use techniques such as methylated RNA immunoprecipitation sequencing (MeRIP - seq) combined with RNA sequencing (RNA - seq) to screen and validate candidate targets of ALKBH5, especially to explore how ALKBH5 inhibits the expression of LY6/PLAUR domain containing 1 (LYPD1) through m6A demethylation.
4. **Verify the oncogenic role of LYPD1 in HCC**: Establish an HCC cell line with LYPD1 knockdown, assess its impact on cell proliferation, migration and invasion ability, and further verify its impact on tumor growth and metastasis through in vivo experiments.

In summary, this study aims to elucidate the mechanism of action of ALKBH5 as a tumor suppressor in HCC, especially by inhibiting the expression of LYPD1 in an m6A - dependent manner, thereby providing new insights into the molecular pathogenesis of HCC and a basis for potential biomarkers and therapeutic targets.